Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.50 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.50 |
| ▸ | OPRK1 known ✓ | P41145 | 1/20 | 0.50 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.50 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.50 |
| ▸ | HDAC6 known ✓ | Q9UBN7 | 1/20 | 0.50 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.96 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 4/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.53 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.53 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.53 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.53 |
| ▸ | BRD4 | O60885 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5724 | 0.98 | CTNNB1 (1.00) | CTNNB1SMN1; SMN2MEN1KMT2AMAPK1 | |
| SCHEMBL27680126 | 0.98 | CTNNB1 (1.00) | CTNNB1SMN1; SMN2MEN1KMT2AMAPK1 | |
| SCHEMBL28876495 | 0.98 | CTNNB1 (1.00) | CTNNB1SMN1; SMN2MEN1KMT2AMAPK1 | |
| SCHEMBL28081666 | 0.96 | CTNNB1 (0.96) | CTNNB1SMN1; SMN2MEN1KMT2AMAPK1 | |
| Methyl Alcohol SCHEMBL8782982 | 0.94 | CTNNB1 (0.93) | CTNNB1SMN1; SMN2MEN1KMT2AMAPK1 | |
| Hydroquinone SCHEMBL28208693 | 0.91 | CTNNB1 (0.86) | CTNNB1SMN1; SMN2MEN1KMT2AMAPK1 | |
| Trifluoroacetic Acid SCHEMBL5478809 | 0.88 | CTNNB1 (0.81) | CTNNB1SMN1; SMN2MEN1KMT2AMAPK1 | |
| SCHEMBL7693879 | 0.86 | CTNNB1 (0.77) | CTNNB1SMN1; SMN2MEN1KMT2AIRAK4 | |
| SCHEMBL1892492 | 0.85 | CTNNB1 (0.77) | CTNNB1SMN1; SMN2MEN1KMT2AMAPK1 | |
| SCHEMBL27800575 | 0.85 | CTNNB1 (0.77) | CTNNB1SMN1; SMN2MEN1KMT2APARP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1605 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113687010-B | Method for accurately distinguishing echinoid-intermediate ball echinoid from commercial gonad of echinoid | 大连海洋大学 | 2023-09-15 | — | — | CN | claimed |
| CN-111743871-B | Phenobenzmine hydrochloride tablet and preparation method thereof | 天方药业有限公司 | 2022-04-19 | — | — | CN | claimed |
| CN-106659789-B | CYP2J2 antagonists in the treatment of pain | 弗劳恩霍夫应用研究促进协会 | 2020-11-03 | — | — | CN | claimed |
| CN-111743871-A | Phenobenzmine hydrochloride tablet and preparation method thereof | 天方药业有限公司 | 2020-10-09 | — | — | CN | claimed |
| CN-104857515-B | Drug core composition for controlled release drug delivery and osmotic pump preparation containing the same | 中国科学院上海药物研究所 | 2020-01-10 | — | — | CN | claimed |
| EP-1898886-B1 | NOVEL SUSTAINED RELEASE DOSAGE FORM | RUBICON RES PVT LTD (IN) | 2019-09-04 | — | — | EP | claimed |
| WO-2018172733-A1 | COMBINATIONS OF POLYMYXINS | HELPERBY THERAPEUTICS LIMITED (GB) | 2018-09-27 | — | — | WO | claimed |
| EP-2613774-B1 | COMBINATION OF PHENOXYBENZAMINE AND POLYMIXINE E TO TREAT MICROBIAL INFECTIONS | HELPERBY THERAPEUTICS LTD (GB) | 2018-03-28 | — | — | EP | claimed |
| US-9757376-B2 | Pharmaceutical compositions | GM PHARMACEUTICALS, INC. (US) | 2017-09-12 | — | — | US | claimed |
| CN-106659789-A | Cyp2j2 antagonists in the treatment of pain | 弗劳恩霍夫应用研究促进协会 | 2017-05-10 | — | — | CN | claimed |
| CN-1260980-A | Oral-applied medicine for curing impotence and preparing process thereof | JIANG YANG (CN) | 2000-07-26 | — | — | CN | claimed |
| WO-2000021504-A1 | ENCAPSULATION OF SENSITIVE LIQUID COMPONENTS INTO A MATRIX TO OBTAIN DISCRETE SHELF-STABLE PARTICLES | GENERAL MILLS, INC. (US) | 2000-04-20 | — | — | WO | claimed |
| EP-0935523-A4 | EMBEDDING AND ENCAPSULATION OF CONTROLLED RELEASE PARTICLES | GEN MILLS INC (US) | 1999-12-29 | — | — | EP | claimed |
| EP-0935523-A1 | EMBEDDING AND ENCAPSULATION OF CONTROLLED RELEASE PARTICLES | GENERAL MILLS, INC. (US) | 1999-08-18 | — | — | EP | claimed |
| WO-1998018610-A1 | EMBEDDING AND ENCAPSULATION OF CONTROLLED RELEASE PARTICLES | LENGERICH BERNHARD H VAN (US) | 1998-05-07 | — | — | WO | claimed |
| EP-0723443-A1 | USE OF ALPHA RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CHRONIC MUSCLE PAIN | MYOTECH, INC. (US) | 1996-07-31 | — | — | EP | claimed |
| WO-1995010275-A1 | USE OF ALPHA RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CHRONIC MUSCLE PAIN | HUBBARD DAVID R JR (US) | 1995-04-20 | — | — | WO | claimed |
| US-5328453-A | Method for enhancing transdermal drug delivery of electrical drug applicators | DRUG DELIVERY SYSTEMS INC. (US) | 1994-07-12 | — | — | US | claimed |
| CN-1078886-A | New medicine \" Zhulinan \" for treating prostatic hyperplasia and uropathy | YU CHANGHU (CN) | 1993-12-01 | — | — | CN | claimed |
| US-4532135-A | Treating renal damage by administering vasodilator having postsynaptic alpha-adrenoceptor blocking activity and antihyperlipidemic characteristics | EDWARDS K DAVID G | 1985-07-30 | — | — | US | claimed |